Novartis Ag Adr (NVS)

Nov 19, 2025

Morgan Stanley Upgrades Novartis (NVS) to Overweight, Raises Price Target to CHF 110 - Finviz

Nov 19, 2025

Nov 19, 2025

Hospital Care Collaboration and Licensing Agreements Analysis Report and Directory 2025: Upfront, Milestone, and Royalties for 726 Deals by Company A-Z, Therapy Focus and Technology Type - GlobeNewswire Inc.

Nov 19, 2025

Nov 13, 2025

Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint - Finviz

Nov 13, 2025

Nov 06, 2025

Novartis Issues $6 Billion in Debt Securities to Bolster Financial Strategy - The Globe and Mail

Nov 06, 2025

Oct 29, 2025

Novartis' Strong Branded Drug Portfolio Supports Steady Long-Term Growth - Morningstar

Oct 29, 2025

Oct 29, 2025

Novartis ADR earnings missed by $0.02, revenue topped estimates - Investing.com India

Oct 29, 2025

Oct 28, 2025

Novartis completes acquisition of Tourmaline Bio - Novartis

Oct 28, 2025

Oct 28, 2025

'Merger Monday' Makes Comeback As US M&A Tops $80 Billion In 24 Hours - Sahm

Oct 28, 2025

Oct 28, 2025

Novartis Lags Q3 Earnings, Announces $12B Avidity Biosciences Acquisition - Yahoo Finance

Oct 28, 2025

Oct 28, 2025

Novartis announces expiration of Tourmaline Bio tender offer - Novartis

Oct 28, 2025

Oct 27, 2025

Stocks Rally on US-China Preliminary Trade Agreement - Barchart.com

Oct 27, 2025

Oct 27, 2025

Avidity Biosciences Soars After $72 Per Share Novartis Takeover - Sahm

Oct 27, 2025

Oct 27, 2025

Market movers: Qualcomm, Avidity Biosciences, Lululemon, Keurig Dr Pepper… - Proactive financial news

Oct 27, 2025

Oct 27, 2025

Novartis to acquire Avidity Biosciences in $12B deal - Proactive financial news

Oct 27, 2025

Oct 27, 2025

Avidity Shareholders Win Big As Novartis Moves Fast On $12 Billion Deal - Sahm

Oct 27, 2025

Oct 27, 2025

Why Avidity Biosciences Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket - Benzinga

Oct 27, 2025

Oct 26, 2025

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline - Novartis

Oct 26, 2025

Oct 24, 2025

Jim Cramer: Time To 'Pull The Trigger' On Kratos, A 'Terrific' Stock - Sahm

Oct 24, 2025

Oct 22, 2025

Novartis Cosentyx Trial Shows Efficacy In Patients With Stiff Joints And Muscle Pain - Sahm

Oct 22, 2025

Oct 22, 2025

Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer - Novartis

Oct 22, 2025

Oct 20, 2025

Will Positive Regulatory Updates Further Boost INCY Stock? - The Globe and Mail

Oct 20, 2025

Oct 17, 2025

Novartis Cancer Drug Shows Sustained Benefit In Five-Year Breast Cancer Trial - Sahm

Oct 17, 2025

Oct 16, 2025

Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity - Sahm

Oct 16, 2025

Oct 16, 2025

Novartis Strengthens Kidney Disease Pipeline With Promising Data - Sahm

Oct 16, 2025

Oct 15, 2025

Next-Generation Targeted Therapies Reshape Precision Oncology Landscape - Sahm

Oct 15, 2025

Oct 14, 2025

Vor Bio's Collaborator Delivers Positive Results For Telitacicept In Autoimmune Disorder That Impacts Tears - Sahm

Oct 14, 2025

Oct 13, 2025

Will the Orbital Acquisition Strengthen BMY's Cell Therapy Portfolio? - The Globe and Mail

Oct 13, 2025

Oct 11, 2025

UBS Reaffirms Their Hold Rating on Novartis AG (NOVN) - The Globe and Mail

Oct 11, 2025

Oct 08, 2025

Should You Buy Novartis Stock Before October 28? - Barchart.com

Oct 08, 2025

Oct 08, 2025

Barclays Reaffirms Their Sell Rating on Novartis AG (NOVN) - The Globe and Mail

Oct 08, 2025

Oct 04, 2025

2 Surefire Dividend Stocks to Buy for the Long Haul - sharewise.com

Oct 04, 2025

Oct 03, 2025

Novartis: Superstars Entresto And Kisqali Fuel Market Outperformance (NYSE:NVS) - Seeking Alpha

Oct 03, 2025

Sep 30, 2025

Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU) - Ariva

Sep 30, 2025